

## *Shilpa Medicare Limited*

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

Dated: 12<sup>th</sup> December, 2023

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.  
Ref: Stock Code: NSE: SHILPAMED/BSE-530549

### **Approval by TGA, Australia for Shilpa Medicare Ltd. Unit VI, Bengaluru.**

This is to inform you that Shilpa Medicare Limited, Unit VI, Dabaspeth, Bengaluru, Karnataka, India has received approval from TGA, Australia for manufacture, labeling, packaging and testing of medicinal Oral Mouth Dissolving Films (Wafers).

This Unit of Shilpa Medicare is engaged in the manufacture and testing of Oral Mouth Dissolving Films and Transdermal Patches. The Unit is approved by MHRA, UK. This approval from TGA, Australia is for “wafer” dosage forms as Over-The-Counter medicines.

This Unit is supplying Oral Film products to US and other markets. This approval will enable the company to secure approval and market its Oral Film products in Australia.

Oral Mouth Dissolving Film is a technology intensive, niche dosage form which offers significant advantages over conventional oral dosage forms in terms of patient convenience, dosing compliance and quick and effective delivery of drugs. The company has a pipeline of products in this type of dosage form.

With Regards,

For SHILPA MEDICARE LIMITED

Ritu Tiwary  
Company Secretary & Compliance Officer